Rhythm Pharmaceuticals (RYTM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Rhythm Pharmaceuticals faces a business ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of ...

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have earned an average recommendation of “Moderate Buy ...

Handelsbanken Fonder AB lessened its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 11.9% in the 4th quarter, HoldingsChannel reports. The institutional investor ...

Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its fourth quarter and full year 2024 financial results and recent ...

10 analysts have shared their evaluations of Rhythm Pharmaceuticals RYTM during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed ...

Investing.com - Rhythm Pharma (NASDAQ: RYTM) reported third quarter EPS of $-0.76, in line with the analyst estimate of $-0.76.

In the last three months, 7 analysts have published ratings on Rhythm Pharmaceuticals (NASDAQ:RYTM), offering a diverse range of perspectives from bullish to bearish. The following table ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...

BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...